Promentis Pharmaceuticals

Promentis Pharmaceuticals is a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders. Promentis' drug development programs focus on activating the only known target to restore imbalances in glutamatergic neurotransmission and oxidative stress, which are key factors in cortical dysfunction associated with multiple central nervous system disorders. The company’s lead compound, SXC-2023, is being developed for the treatment of various psychiatric conditions, with an initial focus on disorders that, despite representing common conditions affecting millions of patients, lack FDA-approved treatments and reflect a high level of unmet patient need.